Pan-immune-inflammation value and systemic immune-inflammation index predict the clinical efficacy of biological agents in Crohn’s disease

Both PIV and the SII are useful in predicting efficacy of CD patients treated with biologics. Compared with SII, PIV is a better choice. Key messages What is already known on this topic: Infliximab is the most efficacious and widely used biologic for inducing remission in moderate-to-severe Crohn's disease. SII and PIV have been validated as prognostic indicators in many diseases. What this study adds: Higher PIV and SII both have positive effects on predicting the prognosis of patients with Crohn's disease. Compared with the SII, the PIV holds greater significance in predicting the clinical outcomes for patients with Crohn's disease. How this study might affect research, practice or policy: PIV and SII may aid in risk stratification and individualized treatment planning in Crohn's disease.